Ablexis LLC, of San Francisco, appointed Scott Greer chairman and named Richard Hoffman chief business officer.
Agios Pharmaceuticals Inc., of Cambridge, Mass., appointed John Maraganore to its board.
Ambrilia Biopharma Inc., of Montreal, appointed Faraj Nakhleh to its board.
Aquapharm Biodiscovery, of Oban, Scotland, appointed Tim Morley chief scientific officer.
Ariad Pharmaceuticals Inc., of Cambridge, Mass., named Timothy P. Clackson president of R&D.
Athersys Inc., of Cleveland, elected Jack L. Wyszomierski to its board.
BIND Biosciences Inc., of Cambridge, Mass., appointed Ed Schnipper chief medical officer.
Bioheart Inc., of Sunrise, Fla., appointed Mike Tomas president, CEO and board member, replacing Karl Groth, who will retain his position as chairman. Tomas most recently headed up the Astri Group, a Florida-based early stage private equity investment firm that has had an investment in Bioheart since 2001.
BioVex Inc., of Woburn, Mass., appointed Steven Kelly chief commercial officer.
CalciMedica, of La Jolla, Calif., appointed Steven L. Schoenfeld vice president of clinical development.
Caris Life Sciences, of Irving, Texas, named Dominic P. Moorhead president of European operations.
Cleveland BioLabs Inc., of Buffalo, N.Y., appointed Michael Paterno director of clinical operations.
Codexis Inc., of Redwood City, Calif., named Peter Strumph senior vice president of commercial operations.
Edge Therapeutics Inc., of Newark N.J., appointed 21 scientific advisory board members: E. Francois Aldrich, Gretchen M. Brophy, Fady T. Charbel, E. Sander Connolly Jr., Joseph Dasta, Neal F. Kassell, Hidetoshi Kasuya, Peter D. LeRoux, Stephan B. Lewis, Stephan A. Mayer, J. Paul Muizelaar, J. Mocco, Charles Prestigiacomo, J. Javier Provencio, Denise Rhoney, Jose I. Suarez, Paul M. Vespa, Bryce Weir, Howard Yonas, John H. Zhang and Gregory Zipfel. The company also appointed five business advisors: Geert Cauwenbergh, Kurt Conti, Arthur Klausner, Scott Pallais and Joseph C. Sanginiti.
Fibrocell Science Inc., of Exton, Pa., appointed Nicolas Elian, William K. Boss and Daniel D. Lozano as advisors.
Genetic Technologies Ltd., of Victoria, Australia, appointed Lewis Stuart general manager of its North American molecular diagnostics business.
Idera Pharmaceuticals Inc., of Cambridge, Mass., elected Eve E. Slater to its board.
Illumina Inc., of San Diego, appointed Nicholas J. Naclerio senior vice president of corporate development.
ImmunoGen Inc., of Waltham, Mass., promoted Godfrey Amphlett to vice president of process and analytical development and Robert J. Lutz to vice president of translational R&D.
Jennerex Inc., of San Francisco, appointed Gregory W. Schafer senior vice president and chief financial officer.
Kylin Therapeutics Inc., of West Lafayette, Ind., named John J. Rossi to its scientific advisory board.
MedImmune, of Gaithersburg, Md., appointed Ron Laufer senior managing director of MedImmune Ventures.
MonoSol Rx, of Warren, N.J., appointed Mary Ellen Norvitch vice president, regulatory affairs/clinical affairs/quality assurance and Eric Dadey senior vice president of pharmaceutical development.